Management of Psoriatic Arthritis

Gladman, Dafna D.

doi:10.1016/b978-1-4160-9993-2.00006-0

Cited by 2 publications

(3 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While traditional disease-modifying antirheumatic drugs (DMARD) such as methotrexate appear to offer limited protection from ongoing joint damage in PsA 15 , a newer group of biologic agents, the tumor necrosis factor (TNF) inhibitors, can halt radiographic progression over a period of weeks to years 16,17,18,19 . There are currently 4 TNF inhibitors available to Canadian physicians for treating PsA: etanercept 17,19,20,21,22,23 , infliximab 18,24 , adalimumab 16,25,26 , and golimumab 27 .…”

Section: Rheumatologymentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a Canadian Clinical Practice Setting: The REPArE Trial

Gladman¹,

Bombardier²,

Thorne³

et al. 2011

J Rheumatol

Self Cite

View full text Add to dashboard Cite

Objective.To describe the longterm effectiveness and safety of etanercept in Canadian patients with psoriatic arthritis (PsA), treated over 24 months in clinical practice.Methods.Patients with active PsA (≥ 3 tender and ≥ 3 swollen joints) were recruited from 22 centers. Etanercept was administered at 50 mg/week subcutaneously. In addition to clinical assessment of skin and joint disease, conducted at baseline and at Months 6, 12, 18, and 24, regular patient interviews were conducted by telephone. Patient responses related to health status, disability, and work productivity were scored using the patient global assessment tool, the Health Assessment Questionnaire (HAQ), the Health and Labour Questionnaire (HLQ), and the Fatigue Severity Scale.Results.Out of 110 patients, 71 (65%) maintained etanercept treatment through the end of our study. All clinical measures of disease severity, including joint tenderness/pain, joint swelling, and Psoriasis Area and Severity Index score, improved significantly between baseline and Month 6 of etanercept treatment and remained constant thereafter. By the end of our study, 79% of patients achieved a Psoriatic Arthritis Response Criteria response, and 56% of patients achieved a 0.5-point improvement on HAQ, indicating clinically significant improvement in disability; 14% of patients finished our study free of disability (HAQ = 0). Patients’ work productivity and fatigue improved significantly in parallel with these clinical and functional improvements.Conclusion.Continuous treatment with etanercept over 2 years in a clinical setting improved clinical symptoms of PsA while reducing fatigue, improving work productivity, and ameliorating or eliminating disability.

show abstract

Section: Rheumatologymentioning

confidence: 99%

“…Reasons included lack of efficacy (12 patients), AE (15), withdrawn consent, noncompliance, loss to followup, and protocol violations (12). On average, subjects in our study received 90% (SD 17.4) of the planned doses of the study drug, with a median of 96% (range 13%-100%).…”

Section: Betweenmentioning

confidence: 99%

Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a Canadian Clinical Practice Setting: The REPArE Trial

Gladman¹,

Bombardier²,

Thorne³

et al. 2011

J Rheumatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…3 Although disease modifying antirheumatic drugs have been used to treat psoriatic arthritis, they have not altered the disease course or prevented the progression of joint damage. 4 Since the advent of biological treatments, specifically anti-tumour necrosis factor (anti-TNF) agents, the management of psoriatic arthritis has improved. However, in general, the doses of these drugs have been extrapolated from those used in patients with rheumatoid arthritis, and we do not know whether they are appropriate for patients with psoriatic arthritis.…”

mentioning

confidence: 99%

Etanercept for psoriatic arthritis

Gladman¹

2010

BMJ

View full text Add to dashboard Cite

show abstract

Management of Psoriatic Arthritis

Cited by 2 publications

References 69 publications

Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a Canadian Clinical Practice Setting: The REPArE Trial

Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a Canadian Clinical Practice Setting: The REPArE Trial

Etanercept for psoriatic arthritis

Contact Info

Product

Resources

About